PDF (Download) |
- European Bugleweed (Lycopus europaeus)
- Gypsywort
- Thyroid Function
| Date: 08-31-2008 | HC# 030687-359 |
Re: Observational Study Examines European Bugleweed's Effects on Thyroid
Beer AM, Wiebelitz KR, Schmidt-Gayk H. Lycopus europaeus (Gypsywort): effects on the thyroidal parameters and symptoms associated with thyroid function. Phytomed. Jan 2008;15(1-2): 16-22.
European
bugleweed (Lycopus europaeus; identified in article as gypsywort) is
traditionally used to treat "slight hyperthyroidism with
vegetative-nervous disturbances as well as in tenseness and pain of the mammary
gland." Pre-clinical studies have demonstrated that European bugleweed
extracts have effects on thyroid parameters, including reduction of thyroid
hormones in rats and reduction of the thyroid-stimulating effects of antibodies
obtained from patients with Grave's disease. However, clinical studies have not
shown significant changes in thyroid parameters. Therefore, the purpose of this
prospective observational clinical study was to examine the effect of European
bugleweed on thyroid function and symptoms in patients with symptoms of
hyperthyroidism.
This study was
conducted in 2003-2004. Patients (n=62) were recruited from the Department of
True Naturopathy at Blankenstein Hospital (Hattingen,
Germany). The
patients were included if they had thyroid-stimulating hormone (TSH) levels
less than 1.0 mU/L and symptoms of hyperthyroidism according to naturopathic
practice. These symptoms included nervous inner restlessness, heart
sensations/palpitations, intense perspiration, and pathological heat
intolerance. Patients in track 1 (n=33) received a daily 1-0-1 dose of 20 mg
tablets of a European bugleweed preparation (Thyreo-loges B tablets, Pharm.
Firm Loges, Winsen, Germany) for an average of 15.6
weeks. The track 2 group (n=29) received naturopathic treatment and no placebo.
The main outcome measures were tri-iodothyronine and thyroxine excretion in
urine at visit 1 (admission) and visit 2 (day of discharge from clinical
treatment). Secondary outcome measures included levels of serum free
tri-iodothyronine, free thyroxine, 17-beta-estradiol, testosterone, follicle-stimulating
hormone, luteinizing hormone, and prolactin, as well as blood pressure and
heart rate.
The results
showed no significant differences between the control group and the European
bugleweed group in tri-iodothyronine excretion in urine. Urinary excretion of
thyroxine was significantly higher in the European bugleweed group compared to
the control group (P=0.032). No significant changes were observed in any of the
other outcome measures. In addition, "most patients assessed the efficacy
of the therapy as good." There were 6 adverse event reports. Of these, 1
case was deemed possibly linked to treatment: "disturbances of the cardiac
rhythm" at 7 weeks.
The authors note
that the increase in thyroxine excretion in urine observed in the European
bugleweed group "has to be interpreted with caution and restraint in
respect of the final evidence because of the missing randomization in an
observational study." The results suggest that an interference with
tubular reabsorption in the kidneys or modification of renal excretion
mechanisms within the glomeruli could account for the increased thyroxine
excretion. More research is needed to confirm these results; however this study
is the first to show "a measurable change of thyroid-related hormone
parameters in human beings," related to treatment with European bugleweed.
—Marissa N. Oppel, MS
|